PDCD1 and neoplasm: Furthermore, when combined with anti‐PD‐1 therapy, the M13 phage‐based personalized vaccine eradicates established MC‐38 tumors in 75% of treated animals and they develop 100% resistance against tumor invasion when challenged 5 months after treatment.